

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

**SUPPLEMENTAL ANNOUNCEMENT TO
THE ANNUAL REPORT FOR
THE YEAR ENDED 31 DECEMBER 2020**

Reference is made to the annual report of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2020 published on 14 April 2021 (the “**Annual Report**”). Unless otherwise defined, capitalized terms used herein shall have the same meaning as defined in the Annual Report.

In addition to the information disclosed in the section headed “Share Option Scheme” in notes to consolidated financial statements of the Annual Report, the Company would like to provide additional information in respect of the grant of the share options.

According to the share option scheme (the “**Share Option Scheme**”) adopted by the Company on 18 May 2012, the purpose of the Share Option Scheme is to, among others, (i) motivate eligible participants, including but not limited to the directors, employees and consultants of the Group, and optimise their performance and efficiency for the benefit of the Group; (ii) attract and retain or otherwise maintain on-going business relationships with the eligible participants whose contributions are, will or expected to be beneficial to the Group; and (iii) align the interests of the eligible participants and shareholders of the Company.

On 21 February 2019, a total of 102,000,000 share options and 24,000,000 share options were granted to 5 consultants of the Group (the “**Consultants**”) and employees of the Group respectively. 72,000,000 share options granted to 3 consultants were lapsed during the year ended 31 December 2020. As of 31 December 2020, 30,000,000 share options were remained outstanding and their details are as follows:

Consultant A

Consultant A is a business consultant of the Group, possesses extensive business administration and operations experience in China. She also experienced in business development activities in China. The Company considers that Consultant A will be able to provide assistance for the Group’s business development, whose contribution are expected to be beneficial to the Group. Consultant A was granted with 15,000,000 share options.

Consultant B

Consultant B is a business consultant of the Group, possesses extensive business operation experience in China. The Company considers that Consultant B will be able to provide business advisory for business development for the Group, whose contribution are expected to be beneficial to the Group. Consultant B was granted with 15,000,000 share options.

On 16 November 2020, a total of 50,000,000 share options and 18,900,000 share options were granted to 3 consultants and employees of the Group respectively. As of 31 December 2020, 50,000,000 share options granted to consultants were remained outstanding and their details are as follows:

Consultant C

Consultant C is a technology consultant of the Group. He has extensive working experience in information technology industry and business network in China. The Company considers that Consultant C will be able to provide the latest information technology industry updates related to the Group’s business and business advisory for business development for the Group, whose contribution are expected to be beneficial to the Group. Consultant C was granted with 26,000,000 share options.

Consultant D

Consultant D is a strategic financial planning consultant of the Group. He has extensive experience in investments, merger and acquisitions, investors relationship. The Company considers that Consultant D will be able to make use of his business connections and network in finding potential investors and projects for the Company, whose contribution are expected to be beneficial to the Group. Consultant D was granted with 12,000,000 share options.

Consultant E

Consultant E is sales and marketing consultant of South Asia Region of the Group. He has extensive experience in sales and marketing and operation in food and beverage industry. The Company considers that Consultant E will be able to provide the sales networking related to the Group's businesses and explore the new potential customers in South Asia Region to the Group, whose contribution are expected to be beneficial to the Group. Consultant E was granted with 12,000,000 share options.

None of the grantees of these options are the directors, chief executives or substantial shareholders of the Company, nor an associate (as defined under the Listing Rules) of any of them.

The above information does not affect any other information contained in the Annual Report, and save as disclosed above, all other information in the Annual Report remains unchanged.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 24 August 2021

As at the date of this announcement, the Board comprised the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Mr. Du Dong
Mr. Lo Yuen Wa Peter

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Jia Wenjie
Mr. Zhang Lele

Independent non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen
Mr. Hu Guohua